Clinical Trials Logo

FSGS clinical trials

View clinical trials related to FSGS.

Filter by:

NCT ID: NCT01468493 Recruiting - FSGS Clinical Trials

A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients

SuparSDRF
Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

NCT ID: NCT01451489 Terminated - FSGS Clinical Trials

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

FSGS
Start date: October 13, 2011
Phase: N/A
Study type: Interventional

This is a prospective,multicentre study to compare the efficacy, safety, tolerability and relapse of FK506 versus CTX in the treatment of severe Focal Segmental Glomerulosclerosis (FSGS).

NCT ID: NCT01164098 Terminated - Proteinuria Clinical Trials

Rituximab to Prevent Recurrence of Proteinuria

Start date: February 2012
Phase: Phase 3
Study type: Interventional

The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS). The proposed study has strong clinical implications, since it may extend the approved indications for rituximab treatment to recurrent FSGS as well as to other proteinuric diseases. Furthermore, it will offer new insights into the role of sphyngomyelin related enzymes in podocyte function in health and disease, thus allowing the identification of novel targets for antiproteinuric drug development. Finally, the proposed study offers the opportunity to identify a correlation between the patient's specific clinical outcome and the experimental results obtained after exposing podocytes to patient sera in the presence or absence of rituximab. Therefore, it may lead to the development of an assay for the pre-transplant identification of patients at high-risk for recurrent disease and, among them, may allow the identification of those patients that will respond to rituximab.